These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 37520563)

  • 1. Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids.
    Beelen NA; Aberle MR; Bruno V; Olde Damink SWM; Bos GMJ; Rensen SS; Wieten L
    Front Immunol; 2023; 14():1133796. PubMed ID: 37520563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
    Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
    Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
    BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression.
    Masu T; Atsukawa M; Nakatsuka K; Shimizu M; Miura D; Arai T; Harimoto H; Kondo C; Kaneko K; Futagami S; Kawamoto C; Takahashi H; Iwakiri K
    PLoS One; 2018; 13(12):e0200664. PubMed ID: 30596643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.
    Juliá EP; Amante A; Pampena MB; Mordoh J; Levy EM
    Front Immunol; 2018; 9():2140. PubMed ID: 30294328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tribody [(HER2)
    Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
    Front Immunol; 2018; 9():814. PubMed ID: 29725336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
    Cooley S; Burns LJ; Repka T; Miller JS
    Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation.
    Eitler J; Rackwitz W; Wotschel N; Gudipati V; Murali Shankar N; Sidorenkova A; Huppa JB; Ortiz-Montero P; Opitz C; Künzel SR; Michen S; Temme A; Loureiro LR; Feldmann A; Bachmann M; Boissel L; Klingemann H; Wels WS; Tonn T
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38417916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer.
    Li F; Liu S
    Front Immunol; 2022; 13():1083462. PubMed ID: 36601109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.
    Boyerinas B; Jochems C; Fantini M; Heery CR; Gulley JL; Tsang KY; Schlom J
    Cancer Immunol Res; 2015 Oct; 3(10):1148-1157. PubMed ID: 26014098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy.
    Clémenceau B; Gallot G; Vivien R; Gaschet J; Campone M; Vié H
    J Immunother; 2006; 29(1):53-60. PubMed ID: 16365600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Degranulation assay to evaluate NK cell natural and antibody-dependent cell-mediated cytotoxicity against A549 tumor spheroids.
    Lopez-Pardo A; Amarilla-Irusta A; Sandá V; Stan-Fontoba M; Borrego F; Amo L
    Methods Cell Biol; 2024; 189():97-115. PubMed ID: 39393889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
    Collins DM; Madden SF; Gaynor N; AlSultan D; Le Gal M; Eustace AJ; Gately KA; Hughes C; Davies AM; Mahgoub T; Ballot J; Toomey S; O'Connor DP; Gallagher WM; Holmes FA; Espina V; Liotta L; Hennessy BT; O'Byrne KJ; Hasmann M; Bossenmaier B; O'Donovan N; Crown J
    Clin Cancer Res; 2021 Feb; 27(3):807-818. PubMed ID: 33122343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy.
    Nikkhoi SK; Li G; Eleya S; Yang G; Vandavasi VG; Hatefi A
    Front Immunol; 2022; 13():1039969. PubMed ID: 36685519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-Dependent Cell-Mediated Cytotoxicity Through Natural Killer (NK) Cells: Unlocking NK Cells for Future Immunotherapy.
    Chin DS; Lim CSY; Nordin F; Arifin N; Jun TG
    Curr Pharm Biotechnol; 2022; 23(4):552-578. PubMed ID: 34414871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity.
    Schettini J; Kidiyoor A; Besmer DM; Tinder TL; Roy LD; Lustgarten J; Gendler SJ; Mukherjee P
    Cancer Immunol Immunother; 2012 Nov; 61(11):2055-65. PubMed ID: 22543528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages.
    Ehlers FAI; Mahaweni NM; van de Waterweg Berends A; Saya T; Bos GMJ; Wieten L
    Cancer Immunol Immunother; 2023 Jun; 72(6):1789-1801. PubMed ID: 36656341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells.
    Hsieh YT; Aggarwal P; Cirelli D; Gu L; Surowy T; Mozier NM
    J Immunol Methods; 2017 Feb; 441():56-66. PubMed ID: 27939300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting.
    Eitler J; Wotschel N; Miller N; Boissel L; Klingemann HG; Wels W; Tonn T
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells.
    Carson WE; Parihar R; Lindemann MJ; Personeni N; Dierksheide J; Meropol NJ; Baselga J; Caligiuri MA
    Eur J Immunol; 2001 Oct; 31(10):3016-25. PubMed ID: 11592078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.